Can an Epilepsy Drug Be the Answer to Preventing Alzheimer’s Dementia?

Doctor shows the patient how to use daily dose pills

An exciting research study has concluded at Johns Hopkins University and the results could be great news for the millions of patients who suffer from Alzheimer’s dementia. Epilepsy is a common neurological disorder that affects more than 50 million people in the world. A new drug, antiepileptic levetiracetam, has proved to be successful in reducing […]

Continue reading


Newly Discovered Control Switch Key to Saving Cells from Untimely Death

Cell stress magnified by chronic disease All of us undergo stress, but those dealing with chronic illnesses such as cancers, diabetes, inflammatory diseases, and neurological degenerative diseases such as Parkinson’s and Alzheimer’s are at an increased level of danger due to a naturally occurring cell stress control mechanism. However, according to a newly released study, […]

Continue reading


Treating Alzheimer’s disease: A New Chemical Approach

From the University of Liverpool and Callaghan Innovation in New Zealand comes a study that local scientists have been developing; a new kind of chemical approach that will harness the natural ability of complex sugars in the treatment Alzheimer’s disease.   The team of scientists produced a new library of sugars called heparan sulphates, which […]

Continue reading


Alzheimer’s disease: Molecular Chain Reaction Found?

Researchers at Lund University in Sweden headed by Professor Singerup Linse and Erik Helistrand have recently identified a molecular mechanism behind the crucial step in Alzheimer’s that leads to the death of brain cells.   The neurological disease is associated, as a general statement, with memory loss and changes in personality.  The research at Lund […]

Continue reading


Children of Long-lived Parents: Less Risk of Cancer?

  A recently completed study at the University of Exeter showed that people with long-lived parents had a twenty-four percent decreased chance of getting cancer.  The parameters of ‘long-lived’ defined as mothers who lived past ninety-one years and fathers who lived past eighty-seven years. A side study posted from the National Institute for Health and […]

Continue reading


Alzheimer’s in Mice: Drug-reversible?

Within the journal Science, University of Pittsburgh Graduate School of Public Health scientists confirm that a study performed on mouse models of Alzheimer’s disease had significantly improved brain function and memory capabilities after being treated with an anti-cancer drug. The cancer drug, known as bexarotene, has previously been studied and used for the treatment cutaneous […]

Continue reading


Triumphs in Genetic Sequencing of Human Diseases

  At Queen Mary University in London, researchers have conducted the largest study of genetic sequencing of human diseases known to date, identifying the genetic basis of six different diseases: autoimmune thyroid disease, celiac disease, Crohn’s disease, psoriasis, multiple sclerosis, and type 1 diabetes. According to the study, though the exact causes of these diseases […]

Continue reading


Linked: Can Skin Cancer Lower Risk of Alzheimer’s disease?

A study published in the May 2013 online issue of Neurology follows researchers in Minneapolis who performed a study where 1,102 participants, of an averaged an age of 79, were followed for the span of 3.7 years and tested to see if ever they developed dementia. At the start of the study, 109 of the […]

Continue reading


A Promising New Alzheimer’s Drug Stops Memory Loss

According to Northwestern Medicine Research, new experimental molecules have great promise in targeting enzymes in the brain that prevent memory loss in Alzheimer’s disease.  Developed in D. Martin Watterson’s laboratory, the molecules halted memory loss and were able to fix damaged communication between brain cells in mice. Researchers identified and targeted a key enzyme: a […]

Continue reading


Antibodies Effectively Treat Alzheimer’s-like Disease

Drs. David Holtzman and Mac Diamond of the Washington University School of Medicine recently published research in Neuron that outlined the process of studying mice for potential tau protein tangle treatment avenues. Tau is a toxic component of Alzheimer’s and other neurodegenerative diseases, due to the protein’s tendency to amass in tangles.  The aggregates, called […]

Continue reading


ACE Inhibitors and Alzheimer’s Prevention

Cedars-Sinai scientists published a study in Journal of Clinical Investigation that suggests ACE inhibitors, in the right context and at the right time, can be a good thing.   Many people with high blood pressure take ACE inhibitors, medication meant to widen blood vessels by limiting activity of ACE (angiotensin-converting enzyme), a naturally occurring protein. […]

Continue reading


Investigational Therapy Focuses on Slowing Progression in Mild and Moderate

Researchers at Houston Methodist’s Nantz National Alzheimer Center are studying an investigational drug to slow brain cell deterioration in patients with mild to moderate Alzheimer’s disease. T-817MA focuses on preventing brain cell loss and slowing disease progression, where current treatment options like Donepezil, Rivastigmine, and Memantine only treat the symptoms.  The scientists want to know […]

Continue reading


A Vicious Cycle of Alzheimer’s and Diabetic Hypoglicemia?

A study conducted recently at the Univeraity of California- San Francisco published online in  JAMA Internal Medicine. The research was focused in on finding a close link between diabetes and dementia. According to the journal, diabetic patients with low blood sugar may have an increased risk of developing dementia, and patients with dementia or other […]

Continue reading


A New Drug Reverses Lost Brain Connections in Alzheimer’s Disease

Researchers at Sanford-Burnham Medical Research Institute have developed the first experimental drug named NitroMemantine that boosts brain synapses lost to Alzheimer’s disease. The medication combines two FDA-approved drugs to stop destructive cascades within the brain, which destroys the connections between neurons and ultimatly leads to memory loss and a decline in cognition. Dr. Stuart A. […]

Continue reading


Green Tea May Help Prevent Alzheimer’s Disease

Researchers at the Michigan Alzheimer’s Disease Center discovered that flavored ECGC, or epigallocatechi-3-gallate, found in green tea could bind to the toxic protein beta-amyloid and prevent its build-up. When ECGC binds to the protein, it is able to change beta-amyloid’s properties. Dr. Mi Hee Lim, lead researcher of the study, found that ECGC bonded to […]

Continue reading


Alzheimer’s Disease Progression Halted Due to Increased Protein Expression

A recent report from researchers at the Massachusetts General Hospital which identifies a protein that aids the immune system in the removal of A-beta protein from the brain, could lead to new treatments of Alzheimer’s disease. According to cocorresponding author of the report, Dr. Joseph Eli Khoury of the Center for Immunology and Inflammatory Diseases […]

Continue reading


Stem Cells Used to Grow New Neurons, Brain Repair Circuit Identified

Researchers at Duke University have identified a new type of neuron within the adult brain capable of directing stem cells to make new neurons. The experiments are preliminary, but the hope is that the brain one day could be healing itself from within. Chay Kuo, M.D, Ph.D., an assistant professor of cell biology, neurobiology, and […]

Continue reading


The Effects of Parkinson’s disease Mutations Reversed within Cells

A recent study from University of California, San Francisco scientists found that a chemical in anti-wrinkle cream could effectively prevent the death of nerve cells that had been damaged by mutations which cause an inherited form of Parkinson’s disease. According to the study’s senior scientist, UCSF chemist Kevan Shokat, PhD; the study targeted an enzyme […]

Continue reading


A New Study Shows Small-molecule Drug through Blood-Brain Barrier

Mayo clinic researchers demonstrated within a mouse model that a synthetic peptide carrier works to deliver brain cancer chemotherapy drugs, as well as neurological medications. Neuroscientist Gobinda Sarkar, Ph.D, of the Mayo Clinic and corresponding author of the study discussed that they were able to transport eight different molecules, and much less disruptively through the […]

Continue reading


Antidepressant May Slow Progression of Alzheimer’s Disease

According to research by the Washington University School of Medicine, published in Science Translational Medicine, a common antidepressant can reduce the production of brain plaques. Brain plaques correlate closely with memory problems and other cognitive impairments caused by Alzheimer’s disease.  Stopping plaque buildup is believed to help halt the mental decline of Alzheimer’s patients.  Scientists […]

Continue reading


Amino Acids Improve Sleep in Mice with Traumatic Brain Injury

Amino Acids Improve Sleep in Mice with Traumatic Brain Injury  A study by Oregon Health and Science University, published in Science Translational Medicine, discovered a way to fix sleep disturbances in mice suffering from traumatic brain injury.  These results are important, because people commonly experience long-term and severe sleep and wakefulness issues after suffering concussions, […]

Continue reading


Controlling length of mitochondria may cure Alzheimer’s diseases

In a recent study, scientists at the Queensland Brain Institute (QBI) at the University of Queensland and Harvard University have found in their research that the length of the mitochondria may be related to Alzheimer’s treatment. Mitochondria are organelles that metabolize energy for the all the cells. The scientists found in cases where there were […]

Continue reading


Biomarker Could Aid in Revealing Alzheimer’s Early

A new study recently published in the journal Annals of Neurology discussed the identification of what could be the earliest-known biomarker that is associated with the risk of developing Alzheimer’s disease. Results of the study showed that the biomarker was present within Cerebral Spinal Fluid (CSF) for at least a decade before any signs of […]

Continue reading


Michael Mullan: Brain Fitness Programs – a scam ?

Perform a web search on “brain scam” and you will find several articles questioning the veracity of claims made with respect to brain fitness or brain exercise programs. Are these programs a scam? One thing is clear, they appear to be rapidly increasing in popularity – all the way from self help books and DVDs […]

Continue reading


Donation Campaign – 36 hour giving challenge campaign

  Most of the Roskamp Institute’s funding comes from grant funding and the general public — people like you. Your gift makes a difference in the lives of people facing diseases such as Alzheimer’s Disease, Head Trauma, Drug Addiction, Cancer and Tourette’s Syndrome. Your contribution to the not-for-profit (501[c]3) Roskamp Institute is tax deductible and […]

Continue reading


Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide.

The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Abeta peptide that is […]

Continue reading


Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease.

Alzheimer’s disease (AD) is the most common form of dementia among the aging population and is characterized pathologically by the progressive intracerebral accumulation of beta-amyloid (Abeta) peptides and neurofibrillary tangles. The level of proangiogenic growth factors and inflammatory mediators with proangiogenic activity is known to be elevated in AD brains which has led to the […]

Continue reading


Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D.

Alzheimer’s disease (AD) is characterized by excessive cerebrovascular deposition of the β-amyloid peptide (Aβ). The investigation of Aβ transport across the blood-brain barrier (BBB) has been hindered by inherent limitations in the cellular systems currently used to model the BBB, such as insufficient barrier properties and poor reproducibility. In addition, many of the existing models […]

Continue reading


Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease.

Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to progressive cognitive decline. Recent studies from our group and others have suggested that certain G-protein coupled receptors (GPCRs) can influence the processing of the amyloid precursor protein (APP). Earlier, we demonstrated that stimulation of a chemokine receptor, CXCR2, results in enhanced γ-secretase activity and in […]

Continue reading


Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Several large population-based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer disease (AD). However, other studies with drugs of the same class have shown no beneficial clinical effects. To determine whether certain DHPs are […]

Continue reading


Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.

Venlafaxine and its metabolite desvenlafaxine are serotonin-norepinephrine reuptake inhibitors currently prescribed for the treatment of depression. Previously, it was reported that venlafaxine is an inducer of MDR1, the gene responsible for P-glycoprotein (P-gp). The present study expanded upon these findings by examining the effect of venlafaxine and desvenlafaxine on the expression of both P-gp and […]

Continue reading


Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier.

Increasing evidence suggests that the soluble form of the β-amyloid peptide (Aβ) plays a critical role in the pathogenesis of Alzheimer’s disease. Previously, we reported that treatment with certain antihypertensive dihydropyridine (DHP) compounds can mitigate Aβ production in whole cells and reduce brain Aβ burden in a mouse model of Alzheimer’s disease. As Aβ clearance […]

Continue reading


Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid.

We examined the usefulness of brief neuropsychological tests and serum Aβ as a predictive test for detecting MCI/AD in older adults. Serum Aβ levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw. Twenty-eight of the subjects subsequently developed MCI (n = 18) or AD (n = 10) over the […]

Continue reading


Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism.

Alzheimer’s disease (AD) is characterized by the brain accumulation of Aβ peptides and by the presence of neurofibrillary tangles. Aβ is believed to play an important role in AD and it has been shown that certain flavonoids can affect Aβ production. Recently, it was suggested that the Aβ lowering properties of flavonoids are mediated by […]

Continue reading


Roskamp Institute in Sarasota, Florida, have shown that an anatabine compound supplied by Rock Creek has beneficial effects on memory and learning in animal models of Alzheimer’s Disease. Michael Mullan, MD, Ph.D., CEO of the Roskamp Institute and his colleague, Dr. Daniel Paris, published these findings in October, 2011 in the European Journal of Pharmacology

A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss. Dr. Paul Newhouse, a professor of psychiatry at Vanderbilt University Medical Center, led a study which showed that six months of nicotine patch treatment among patients who had mild cognitive impairment […]

Continue reading


Mike Mullan Alzheimer Researcher Comments on: Nicotine May Help Combat Memory Loss study by Dr. Newhouse

A recent study at Vanderbilt University Medical Center conducted by Dr. Paul Newhouse and colleagues suggests that Nicotine patches may be very beneficial in individuals with mild cognitive impairment (MCI). MCI is frequently regarded as a precursor to Alzheimer’s disease and is primarily of the type that demonstrates reduction in memory while most other functions […]

Continue reading


Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model.

Abstract The current lack of diagnostic and prognostic biomarkers for traumatic brain injury (TBI) confounds treatment and management of patients and is of increasing concern as the TBI population grows. We have generated plasma proteomic profiles from mice receiving TBI by controlled cortical impact at either 1.3 mm or 1.8 mm depth, comparing these against those of […]

Continue reading


Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo

Brain Aβ accumulation represents a key pathological hallmark in Alzheimer’s disease. In this study, we investigated the impact of anatabine, a minor alkaloid present in plants of the Solanacea family on Aβ production in vitro using a cell line overexpressing the human amyloid precursor protein (APP) and in vivo using a transgenic mouse model of […]

Continue reading


Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease.

Expression levels of tumor necrosis factor (TNF) receptors, TNFR1 and TNFR2, are significantly changed in the brains and cerebrospinal fluid (CSF) with Alzheimer’s disease (AD). Moreover, we also found that, in an Alzheimer’s mouse model, genetic deletion of TNF receptor (TNFR1) reduces amyloid plaques and amyloid beta peptides (Aβ) production through β-secretase (BACE1) regulation. TNF-α […]

Continue reading


Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons.

The distribution of postsynaptic glutamate receptors has been shown to be regulated by proimmunocytokine tumor necrosis factor α (TNF-α) signaling. The role of TNF-α receptor subtypes in mediating glutamate receptor expression, trafficking, and function still remains unclear. Here, we report that TNF receptor subtypes (TNFR1 and TNFR2) differentially modulate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) clustering […]

Continue reading


Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents.

Gulf War Illness (GWI) is a chronic multisymptom condition with a central nervous system (CNS) component, for which there is no treatment available. It is now believed that the combined exposure to Gulf War (GW) agents, including pyridostigmine bromide (PB) and pesticides, such as permethrin (PER), was a key contributor to the etiology of GWI. […]

Continue reading


Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Sarasota, Fla. – August 1, 2007 The Roskamp Institute released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes.  The study, led by Roskamp’s Dr. Robert Farese, is detailed in the August issue of The Journal of Clinical Investigation, a highly prestigious […]

Continue reading


The Roskamp Institute

The Roskamp Institute, a not-for-profit research Institute, is dedicated to finding cures for neuropsychiatric disorders, with the emphasis on Alzheimer’s disease (AD).  Current research at the Roskamp Institute is focused on dissecting the molecular biological pathways implicated in AD pathogenesis in order to develop therapeutic targets specific to AD etiology. Dr. Michael Mullan (Director of […]

Continue reading


The Traumatic Brain Injury Program at the Roskamp Institute

Among the soldiers who survive conflicts in Iraq and Afghanistan, the traumatic brain injuries account for a larger proportion of their casualties than in any other US war in recent history. According to the Joint Theater Trauma Registry, established by the U.S. Army Institute of Surgical Research, approximately 22 percent of the injured US soldiers […]

Continue reading


Roskamp Institute finds one of the genetic causes for Tourettes syndrome

Tourette syndrome (TS) is a heterogeneous childhood disorder and occurs with a frequency of approximately four to ten per 10,000 in the general population (Mason et al. 1998). The symptoms for Tourette syndrome include multiple motor and one or more vocal tics. These symptoms appear to overlap with other neurobehavioral disorders such as obsessive-compulsive disorder, […]

Continue reading


Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson

August 21, 2007 Sarasota, Fla. – The Roskamp Institute today welcomed U.S. Senator Bill Nelson to its research facility in Sarasota, Florida, where the Senator toured the laboratories and discussed the various types of research currently being conducted at the Institute.   “We thank Senator Nelson for his interest in our research and for coming […]

Continue reading


Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease

Millions of people across the globe suffer from Alzheimer’s disease. It is estimated (Alzheimer’s Association, 2008) that in every 71 seconds someone from the US develops Alzheimer’s disease, and estimations by mid-century shows that the probability of someone developing Alzheimer’s disease is every 33 seconds. At present, there are approximately 5.2 million Americans in all […]

Continue reading


Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations

Based in Sarasota, Florida, The Roskamp Institute is a not-for-profit organization. It has dedicated time to finding cures for several neuropsychiatric disorders with a special emphasis on Alzheimer’s disease (AD). In order to develop therapeutic targets which are specific to Alzheimer’s disease etiology, the scientists engaged in current research at Roskamp Institute focus on dissecting […]

Continue reading


Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe

Nilvadipine, an Alzheimer’s drug developed at the Roskamp Institute in Sarasota announced earlier this year was selected for funding or a large-scale European clinical trial. An international research consortium led by Trinity College Dublin (Ireland) announced more than 500 patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of […]

Continue reading


Roskamp institute studies may lead to better diagnosis

Researchers at the Roskamp Institute have new studies that could lead to better diagnosis and eventual treatment for U.S. military personnel as well as other patients with TBI, commonly known as traumatic brain injuries. Fiona Crawford, Ph.D., associate director of the Institute, a leading research facility for Alzheimer’s disease and other neurological disorders says, “We […]

Continue reading


Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins

The Roskamp Institute has surfaced as a leading and reputable non-for-profit biomedical research organization. It has successfully experimented to find cures for several neurodegenerative disorders and conditions like Alzheimer’s disease. Through the clinical trials division and outpatient clinic, at the institute, thousands of Alzheimer’s patients get superior services and therapeutic treatments. Dr. Michael Mullan is […]

Continue reading


Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers.

The Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Drs. Corbin Bachmeier, Daniel Paris, and Michael Mullan at the Roskamp Institute have been working on ways to improve the removal of the Alzheimer amyloid peptide from the brain. Using […]

Continue reading


Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research

Dr. Mullan Alzheimer Research Institute helps high school student to be involved in research……… Roskamp Institute aids high school students in genetic research Roskamp aids high school students in genetic research By JENNIFER RICH – jrich@bradenton.com They look like scientists in their white coats, working in the Roskamp Institute’s lab using microscopes and high-tech research […]

Continue reading


The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels.

The Roskamp Institute has had a long-term interest in finding new treatments for Alzheimer’s disease. Central to the goal of the institute is finding new ways to lower the accumulation of Alzheimers Abeta peptide in the brain. Drs. Michael Mullan and Daniel Paris and colleague investigated the role of an extract of tobacco, known as […]

Continue reading


Dr. Mullan Alzheimer Presentation at Pines of Sarasota

Alzheimer’s disease: Amyloid Plaque (Excerpt from “On The Forefront”)  Video shows Dr. Michael Mullan (Dr. Mullan Alzheimer Researcher at the Roskamp Institute) presenting information to audience about Alzheimer’s Disease.Beta Amyloid Presentation By Dr. Michael Mullan (Mullan Alzheimer Researcher)

Continue reading


Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan

Dr. Fiona Crawford presentedVideo of Alzheimer Research Institute Headed By Dr. Mullan Presentation on Traumatic Brain Injury a synopsis of her recent study of traumatic brain injury (TBI). Her recently published findings show how TBI can affect the brain’s inflammatory mechanisms, changes in protein levels and cellular pathways, long after the original trauma. Dr. Crawford’s […]

Continue reading


Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide.

A study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the journal Amyloid. Building on previous work by Dr. Michael Mullan showing that the Alzheimer’s Aβ peptide is able to prevent blood vessel growth and inhibit tumor growth, Dr. Michael Mullan and other Roskamp Institute scientists […]

Continue reading


Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan

Medications that reduce inflammation known as non-steroidal anti-inflammatory drugs (NSAIDS) do not improve thinking abilities in normal seniors.  These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that […]

Continue reading


Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease

Non-steroidal anti-inflammatory (NSAIDS) drugs such as Naproxen and Celecoxib do not improve cognition in at-risk older adults. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that took […]

Continue reading


Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade”

Laila Abdullah will be presenting the paper on Friday (7/2/2010) at Roskamp Institute. Title:Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade Journal: PNAS 5622–5627 | March 23, 2010 | vol. 107 | no. 12 Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter […]

Continue reading


Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease”

Nowell (Jim) Ganey will be presenting the paper on Friday (6/25/2010) at Roskamp Institute. Title:The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease. Journal : Biomaterials. 2010 Jul;31(21):5608-18. Epub 2010 Apr 28. Journal Club is held every Friday between 4 Pm-5pm. For change in […]

Continue reading


News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program

The Roskamp Institute has been nominated for a Business/Education Partnership Award through the School District of Manatee County‘s ePIE program. Since 1990, this awards program recognizes businesses, organizations, and individuals who have made the commitment to work together to enhance education in the School District of Manatee County. The awards ceremony will be held in August. […]

Continue reading


News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project

On Tuesday June 15th the Roskamp Institute was recognized by the South East High School  Technical Student association for partnering will the in a diabetes project.  At the Victory celebration banquet held at South East High following the TSA teams success in the State TSA finals. The Diabetes project was awarded second place in the […]

Continue reading


News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS

The Roskamp Institute continues to actively recruit clinical research participants for the treatment of both Alzheimer’s disease and Multiple sclerosis. We are proud to share the following press announcement regarding a clinical trial/potential treatment that Roskamp Institute has been involved in since 2006: “FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to […]

Continue reading


Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis”

Scott Ferguson will be presenting the paper on Friday (6/18/2010) at Roskamp Institute. Title:NF-κB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis Journal: Brain, Behavior, and Immunity doi:10.1016/j.bbi.2010.04.005 Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page. […]

Continue reading


Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice

Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice by Rhein et al. Alex Bishop will be presenting the paper on Friday (6/11/2010) at Roskamp Institute. Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page. The Roskamp […]

Continue reading


Event: Journal Club

Benoit Mouzon will be presenting “Blood-brain barrier breakdown and repair by Src after thrombin-induced injury” by Liu et al. The journal club will start at 4:00pm on Friday (may 28th 2010) in the auditorium at Roskamp Institute. The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. […]

Continue reading


Announcement

The Roskamp Institute Memory Center and Clinical Trials Division is pleased to announce the addition of Ms. Yahdinah Alvarez to the clinical team.  Ms. Alvarez is an experienced clinical trial coordinator with expertise in Alzheimer’s and Parkinson’s disease studies.  If you or your loved one is suffering with Alzheimer’s disease or Parkinson’s disease, please contact […]

Continue reading


News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit

2nd Annual Science, Technology, Engineering & Math (S.T.E.M.) Summit at USF  Sarasota-Manatee on Saturday,  will start at 9 AM in May 22nd. Dr Crawford will give a speech about women in science. For more information visit S.T.E.M. website. The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and […]

Continue reading


Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2

By Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D. Published in J Neurochem. 2010 Jan;112(1):66-76. Roskamp Institute, Sarasota, Florida, USA. npatel@scripps.edu Abstract Beta-amyloid peptides (Abeta) are the major constituents of senile plaques and cerebrovascular deposits in the brains of Alzheimer’s disease patients. We have shown previously that […]

Continue reading


Do You Or Someone You Care For Suffer From Alzheimer’s Disease?

ALZHEIMER’S DISEASE A research study is being conducted in our area to evaluate an investigational medication for Alzheimer’s disease. Qualified participants may receive: – Study related medical care – Study medication – Compensation for time and travel Please call now for more info:    Dr. Andrew Keegan 941-256-8018 ext. 353 The Roskamp Institute Memory Clinic and […]

Continue reading


Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease

By Daniel Paris*, Nowell J Ganey, Vincent Laporte, Nikunj S Patel, David Beaulieu-Abdelahad, Corbin Bachmeier, Amelia March, Ghania Ait-Ghezala, Michael J Mullan published in Journal of Neuroinflammation 2010, 7:17 Abstract Background: Ab deposits represent a neuropathological hallmark of Alzheimer’s disease (AD). Both soluble and insoluble Ab species are considered to be responsible for initiating the […]

Continue reading


NEWS RELEASE:Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients

Media Contact: Cheryl Rindfleisch, Roskamp Institute 941-256-8018 x356 crindfleisch@rfdn.org or Jeffree Itrich  858-622-5827 jitrich@ucsd.edu May 10, 2010 Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients 18-Month Phase 2 Study is First to Show Combined Benefits of IGIV on Clinical Outcomes and Brain-Imaging Measures Phase 3 Study Now Enrolling Participants at the Roskamp Institute in […]

Continue reading


Journal Club

Jeremy Frieling is presenting “Days-to-criterion as an indicator of toxicity associated with human Alzheimer amyloid- oligomers” by Gandy et al. Location: Roskamp Institute Date: May 14th 2010 Time: 4:00PM The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific […]

Continue reading


FREE MEMORY SCREENING-Sarasota FL

Are you or someone you know suffering from memory loss or forgetfulness? Roskamp Institute is offering FREE MEMORY SCREENING for adults age 60 or older. For an appointment call:               Roskamp Institute 941-256-8018 ext. 349 The Roskamp Institute Memory Clinic and Clinical Trials Division provide a full range of services for individuals with Alzheimer’s disease […]

Continue reading


Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide

By Daniel Paris • Nikunj Patel • Nowell J. Ganey • Vincent Laporte • Amita Quadros • Michael J. Mullan Int J Pept Res Ther (2010) 16:23–3.  DOI 10.1007/s10989-010-9198-8 Abstract: The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, […]

Continue reading


Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease

By Ait-ghezala G, Abdullah L, Volmar CH, Paris D, Luis CA, Quadros A, Mouzon B, Mullan MA, Keegan AP, Parrish J, Crawford FC, Mathura VS, Mullan MJ. Cytokine. 2008 Nov;44(2):283-7. A continuous inflammatory state is associated with Alzheimer’s disease (AD) evidenced by an increase in proinflammatory cytokines around beta-amyloid (Abeta) deposits. In addition, functional loss […]

Continue reading


CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.

By Volmar CH, Ait-Ghezala G, Frieling J, Weeks OI, Mullan MJ. Exp Cell Res. 2009 Aug 1;315(13):2265-74. CD40, a member of tumor necrosis factor receptor superfamily, and its cognate ligand CD40L are both elevated in the brain of Alzheimer’s disease (AD) patients compared to controls. We have shown that pharmacological or genetic interruption of CD40/CD40L […]

Continue reading


Handling Unstructured Data in Biological Research and Clinical Trials

Venkatarajan S. Mathura Complex information that are available in a crude format make computational modeling and processing a difficult objective in Biological and Health care research. Protocol revisions, process flexibility, user adoptability should be considered in mind to develop an user friendly information management solution. There is a great need to integrate data from several […]

Continue reading


Tech Tips:

By Our Mass Spectrometry Guru Jon Reed This will be the first in an ongoing series of technical tips for those interested in biochemistry and mass spectrometry.  Anyone involved with these fields knows there can be considerable headache and heartache that goes hand-in-hand with even the simplest of experiments.  Along the way, I’ve picked up […]

Continue reading


Roskamp Institute-LECOM collaboration

Dr. Corbin Bachmeier of the Roskamp Institute is currently investigating the drug efflux transport interactions of various antidepressants in collaboration with Dr. Gary Levin of the Lake Erie College of Osteopathic Medicine (LECOM) in Bradenton, FL.  Dr. Bachmeier and Dr. Levin are co-investigators of a grant, provided by Wyeth Pharmaceuticals, which examines the interactions of […]

Continue reading


High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients

Alzheimer’s disease is clinically characterized by progressive cognitive decline accompanied by the presence of amyloid plaques and neurofibrillary tangles in the brain of Alzheimer’s patients. A small protein fragment beta-amyloid (Abeta) with 42 amino acids is shown to deposit earlier in the disease process than the slightly shorter form (40 amino acid fragment).  Both species […]

Continue reading


Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

JC Nowell Ganey will present “The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia” on Thursday (29th April 2010) at 4:00pm in Roskamp Institute. You can find the article in the following link. The Roskamp Institute provides a full range of services for individuals with Alzheimer’s disease including diagnostic work-up […]

Continue reading


Alzheimer’s Disease Anti-Inflammatory Prevention Trial

The Roskamp Institute Memory Center is actively following a large number of subjects who participated in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). Although earlier detection and the development of disease modifying treatment continues to be a primary focus of research and several potential compounds are under clinical trial, more prevention studies are needed. The […]

Continue reading


Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease

A methodology is described for use of a 16-hole circular platform task to test spatial memory in mice. Both bright light and a fan were used to motivate mice to escape the platform surface through a single hole containing an attached escape box. For each daily trial, three correlated measures (escape latency, number of errors, […]

Continue reading


Characteristics of thein VitroVasoactivity of β-Amyloid Peptides

Fiona Crawford1, Zhiming Suo, Chunhong Fang and Mike Mullan Roskamp Laboratories, Department of Psychiatry, 3515 East Fletcher Avenue, University of South Florida, Tampa, Florida, 33613 Abstract The β-amyloid (Aβ1–40) peptide has previously been shown to enhance phenylephrine contraction of aortic ringsin vitro.We have employed a novel observation, that Aβ peptides enhance endothelin-1 (ET-1) contraction, to […]

Continue reading


Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease

Daniel Paris email, Nowell J Ganey email, Vincent Laporte email, Nikunj S Patel email, David Beaulieu-Abdelahad email, Corbin Bachmeier email, Amelia March email, Ghania Ait-Ghezala email and Michael J Mullan email The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA author email corresponding author email Journal of Neuroinflammation 2010, 7:17doi:10.1186/1742-2094-7-17 Published: 8 March 2010 […]

Continue reading


Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US

By Cheryl A. Luis, Andrew Keegan, and Michael Mullan Int J Geriatr Psychiatry. 2009 Feb;24(2):197-201. Suitable methods of earlier detection of memory changes, before the full onset of a dementia are needed.  Methods such as imaging for abnormal protein accumulation in the brain and lumbar puncture to measure abnormal proteins in cerebral spinal fluid are […]

Continue reading


Volunteers for early detection of cognitive decline in older adults

Dr. Cheryl Luis of the Roskamp Institute was awarded a New Investigator Research Grant from the Alzheimer’s Association in 2009.  She is studying the potential usefulness of a blood test in combination with a paper and pencil memory test for early detection of cognitive decline in older adults.  Additional research volunteers are needed.  If you […]

Continue reading


Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association.

Sarasota, FL The Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Presented was “A Reason to Hope”, an Alzheimer’s Services and Treatment Update. The meeting was well attended by caregivers and local community leaders. Dr. Cheryl Luis, Associate Clinical Director of the Roskamp Institute Memory Center, presented some of her current research […]

Continue reading


Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease.

Sarasota, Fla. Dr. Daniel Paris, a senior scientist of the Roskamp Institute, was awarded an Investigator Initiated Research Grant Award from the Alzheimer’s Association to investigate the preclinical efficacy of a natural compound (celastrol) in a genetically engineered mouse model of Alzheimer’s disease. The brain of Alzheimer’s disease patients is characterized by the accumulation of […]

Continue reading


Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease.

Sarasota, FL The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer’s disease and have identified a potential target for developing novel therapeutics for intervention in this disease. The study, led by Roskamp Institute’s Pancham Bakshi, Ph.D., is detailed in the American Chemical Society’s Chemical Biology Journal, a […]

Continue reading


Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Sarasota, FL Sarasota’s Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laboratory research with direct mentoring from internationally-recognized scientists. Roskamp is an Affiliated Research Centre (ARC) of the United Kingdom’s Open University (OU) and was recently granted a license from the […]

Continue reading


Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals

Sarasota, FL Roskamp Institute was the focus of Southeast High Technology Student Association (TSA) team project in the Medical Technology category which was awarded fifth place in the Nation at the 31ST Annual TSA National Conference in Denver, Colorado June 28 – July 2 after wining first place in the State of Florida competition held […]

Continue reading


Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease

This summer, researchers from Roskamp Institute in Sarasota, FL, will begin testing an investigational approach to slowing down the progression of Alzheimer’s disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is currently used to treat primary immunodeficiency disorders but is not currently approved for treating AD, which is one of the […]

Continue reading


World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research

Alzheimer’s disease carries an annual price tag of $148 billion dollars, not to mention the personal toll that it takes on the over 5.3 million patients and their families. More than 5.3 million Americans are living with Alzheimer’s, and every 72 seconds someone in America develops the disease. According to the Alzheimer’s Association, by mid-century […]

Continue reading


Dementia in Older Women

A recent paper published in the Journal Neurology, which analyzed over 900 people, suggests that almost half of all women in their nineties are suffering from dementia. The study carried out in California is one of a few looking specifically at the rates of dementia in the very old. However, given our increased life expectancies, […]

Continue reading


Alzheimer’s and Blood Pressure

The relationship between blood pressure and Alzheimer’s disease is complex. However, we do know that blood pressure raised in mid-life (hypertension) is a risk for the development of Alzheimer’s disease later on. Uncontrolled hypertension is a risk for dementia in general. In fact, stroke related dementias are primarily caused by either clotting or small bleeds […]

Continue reading


What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease?

Alzheimer’s disease is a neurodegenerative disorder (i.e., one which attacks neurons in the brain) which robs us of our memories, language, reasoning and thought. However, the clinical picture of Alzheimer’s has a very distinctive pattern which distinguishes it from other forms of dementia (dementia is a general term which simply means the loss of memory, […]

Continue reading


Double Amyloid Causes Memory Loss

A recent paper (June 22nd from scientists from Harvard University and Trinity College, Dublin) has shown that the amyloid protein is most toxic to memory when it appears in a double form. The researchers extracted the amyloid protein (the small protein that has long thought to be the cause of Alzheimer’s) from the brains of […]

Continue reading


First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease

In 1991, researchers currently at the Roskamp Institute published a paper in the highly prestigious Nature journal entitled “Early Onset Alzheimer’s Disease Caused by Mutations of the Amyloid Gene”. This and related findings were historic milestones in the understanding of the causes of Alzheimer’s disease. Today, seventeen years later, Roskamp Institute researchers are delighted to […]

Continue reading


Alzheimer’s Disease Drug development

An article in the Wall Street Journal on the 18th of June 2008, encapsulates the current expectation, hope and knowledge in the field of Alzheimer’s disease research. Researchers at the Roskamp Institute (Institute) have been part of the history of the discovery of new possibilities for stopping this devastating disease. The article importantly discusses the […]

Continue reading


Traumatic Brain Injury in the War Zone

An article in the New England Journal of Medicine entitled “Traumatic Brain Injury in the War Zone” details the experiences of a supply officer with a US Army Stryker Brigade after suffering a head injury in Northern Iraq in a convoy transporting Iraqi volunteers to Mosul for military training. The officer reported remembering that the […]

Continue reading


ABeta as Antiangiogenic drug

Roskamp Institute has previously worked extensively on the ability of amyloid (the main protein that causes Alzheimer’s disease) to stop the growth of blood vessels. Although this is bad news in Alzheimer’s and probably contributes to the decline in cognitive function the effect has been turned to good use in other areas. The Roskamp Institute […]

Continue reading


Roskamp Institute examines the cellular responses to biological warfare agents

In September of 2004, the research advisory committee on Gulf War veteran’s illnesses produced a report and recommendation on the scientific progress and understanding the complex condition known as Gulf War Syndrome. This report suggested that important contributors to Gulf War Syndrome included the nerve agent prophylaxis pill, pyridostigmine bromide, pesticide exposure and potentially anthrax […]

Continue reading


Genetic manipulation of CD40L reduces Tau phosphorylation

Mainly two cerebral lesions characterized Alzheimer’s disease (AD): an extracellular deposition of the beta-amyloid peptide (Abeta) in senile plaques and an intracellular accumulation of neurofibrillary tangles (principally composed of protein tau). Besides these lesions, a continuous inflammatory state exists in the brain of AD patients. In AD brains, the tau protein becomes hyper-phosphorylated and acquires […]

Continue reading


The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production

Alzheimer disease is the most common cause of dementia, afflicting 24 million people worldwide. Over time, Alzheimer’s disease gradually destroys a person’s memory and ability to learn and carry out daily activities. In addition; individuals may also experience changes in personality and behavior. Alzheimer disease is accompanied by the presence of amyloid plaques and neurofibrillary […]

Continue reading


Potent antiangiogenic motif in amyloid beta

Roskamp Institute study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the scientific journal Amyloid. Work by Dr. Michael Mullan and Dr. Daniel Paris showed that a protein central to Alzheimer’s disease pathology is also able to prevent blood vessel growth and stop tumors. In our […]

Continue reading


CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF)

Alzheimer’s disease (AD) is the most common type of dementia in the elderly. AD is mainly characterized by the accumulation of a small molecule (known as amyloid beta (Abeta)) in the brain. Many researchers have shown that the molecule CD40L is elevated in AD patients. Roskamp Institute research group headed by Dr. Michael Mullan also […]

Continue reading


Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide

A study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the journal Amyloid. Building on previous work showing that the Alzheimer’s Aβ peptide is able to prevent blood vessel growth and inhibit tumor growth, Roskamp Institute scientists investigated particular sequences within the Alzheimer’s Aβ peptide in […]

Continue reading


Effect of NSAIDS on cognitive ability of Alzheimer’s Patients

Medications that reduce inflammation known as non-steroidal anti-inflammatory drugs (NSAIDS) do not improve thinking abilities in normal seniors. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that […]

Continue reading


NSAIDS and their effect on Alzheimers disease

Non-steroidal anti-inflammatory (NSAIDS) drugs such as Naproxen and Celecoxib do not improve cognition in at-risk older adults. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology.  The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that took […]

Continue reading


Roskamp Institute Receives Lung Cancer Research Grant

The James & Esther King Biomedical Research Program has awarded Dr. Daniel Paris of The Roskamp Institute the Small Business Technology Transfer Grant for $100,000 to conduct a research project titled: “Treatment of Lung Adenocarcinoma and Metastasis by Anti-angiogenic Fragments of Abeta.”  The Institute has previously shown that the Abeta peptite can help inhibit the […]

Continue reading


Roskamp Institute Recognized for Its Beautification Efforts

The Sarasota Herald Tribune reported yesterday that the Roskamp Institute was nominated for an Image Manatee Beautification Award. The Manatee Chamber of Commerce recognizes local businesses and organizations each quarter that contribute to the natural beauty of the area through their building design, use of drought-resistant landscaping, and other factors. Visit the Roskamp Institute website […]

Continue reading


Roskamp Institute Helps Florida’s Economy

FloridaTrend.com, a site covering business issues, explained in its article “SOUTHWEST: Eye Opener” on April 1st that the Roskamp Institute’s new neuroscience doctorate program is attracting researchers to Manatee County, which is suffering from layoffs in the home construction sector. These researchers and the facility’s work help bring more money to the county’s economy. Learn […]

Continue reading


Roskamp Institute Supports Moves for Greater State Funding of Biotech Research

Roskamp Institute Director Dr. Michael Mullan was one of many who represented the biotech industry at the Biotechnology Legislative Caucus yesterday to request more state funding in helping the industry thrive in the state. This is important to Florida this would help the state diversify its economy more, and many organizations within the state have […]

Continue reading


Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants

As reported in today’s Bradenton Herald, the Roskamp Institute is searching for clinical trial participants for two potential Alzheimer’s disease treatments. Bapineuzumab and ELND005 are being tested; both hope to successfully remove plaque from the brain which helps cause the condition. For more information please visit the Roskamp Institute Clinical Trial Division web page.

Continue reading


Roskamp Institute Will Host Neuroscience Doctorate Research Program

The Roskamp Institute announced today that it will host a neuroscience doctorate research program as part of The Open University’s — of Milton Keynes, England — Affiliated Research Centre. This is the first program of this kind in Florida and will help students prepare better for researching Alzheimer’s disease and related disorders as they work […]

Continue reading


Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study

The Roskamp Institute announced on December 14, 2007 that an independent Tokyo Medical University study validates its ongoing research into the Alzheimer’s Disease drug Nilvadipine which is in testing. The International Journal of Geriatric Psychiatry details the results of study that suggests that Nilvadipine can prevent in people with memory problems the onset of Alzheimer’s. […]

Continue reading


Roskamp Institute Receives Award of Appreciation

On December 6, 2007 the Economic Development Council (EDC) of the Manatee Chamber of Commerce presented the Roskamp Institute with the 2007 Innovation and Technology Award. The EDC honored the Institute since it has made meaningful contributions to scientific research as it studies neuropsychiatric and neurodegenerative conditions, especially Alzheimer’s Disease. The Roskamp Institute and EDC […]

Continue reading


Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s

The Roskamp Institute is currently determining whether beta-amyloid, a protein, is useful in the screening of individuals who are at risk of developing Alzheimer’s Disease and monitoring how current sufferers are responding to treatments. Scientists at the Institute have published their scientific findings that indicate that beta-amyloid could serve as an important biomarker for the […]

Continue reading


Nilvadipine an anti-hypertensive drug, as a potential treatment for Alzheimer’s disease

    The recent findings showing that certain anti-hypertensive (drugs which lower hypertension) drugs may be helpful in Alzheimer’s disease, is consistent with the work of the Roskamp Institute. The Roskamp Institute has been conducting pioneering research in this area for several years and is currently conducting a clinical trial in Europe to test whether a […]

Continue reading


Anti-hypertension Drugs and Alzheimers

Alzheimers Disease is afflicting millions world wide and the cost of care runs in several billions. Researchers are working hard to find a cure for Alzheimers Disease. Roskamp Insititute, Sarasota, Florida is currently doing clinical trials with Nilvadipine (an anti-hypertension drug that blocks L-type Calcium Channels) in Ireland. Several research is being also conducted to […]

Continue reading


The Traumatic Brain Injury Program at the Roskamp Institute

The Traumatic Brain Injury Program at the Roskamp Institute Among the soldiers who survive conflicts in Iraq and Afghanistan, the traumatic brain injuries account for a larger proportion of their casualties than in any other US war in recent history. According to the Joint Theater Trauma Registry, established by the U.S. Army Institute of Surgical […]

Continue reading


Roskamp Institute Aims to Help Injured Soldiers

Jeremy Willis of the Herald Tribune reports that U.S. Senator Bill Nelson is touring Florida during his congressional August vacation, and Melanie Marquez of the Bradenton Times explains that Nelson learned during his visit to the Roskamp Institute yesterday that it is conducting federally funded research that could help soldiers with traumatic brain injuries. The […]

Continue reading


Down Syndrome Patient Learning New Skills

St. Louis area Down Syndrome patient Colin Goodwin, 18, spent his summer exploring three different jobs while volunteering at a local fire station, reports the Southwest County Journal. St. Louis Arc’s Neighborhood Experiences program matches people like Goodwin who have cognitive conditions with local businesses and organizations to help them develop job skills and establish […]

Continue reading


Tracking Wandering Alzheimer’s Sufferers

One of the biggest fears that Alzheimer’s caregivers have are that those to whom they attend to will wander off — potentially finding themselves lost and in danger.  Associated Press medical writer Lauran Neergaard talks about a few options in her article today titled “Helping find lost Alzheimer’s patients.”  She discusses cheap devices that cost […]

Continue reading


Alzheimer’s Caregiver Training

The Associated Press reports in an article about Alzheimer’s caregiving today that “Offering simple training to people struggling to care for loved ones with Alzheimer’s disease not only eases their burden — it even can keep patients out of nursing homes for an extra 1 1/2 years.” However, many people who care for loved ones […]

Continue reading


The Roskamp Institute Is Good for Manatee County, Florida

The Bradenton Herald reports that at an economic development panel discussion on Friday sponsored by the Manatee Economic Development Council that, as a panelist, Roskamp Institute director Michael Mullan revealed that his organization brings top researchers to the area.  It also provides skilled, technical jobs, but unfortunately it is hard to find suitable lab technicians […]

Continue reading


Sarkozy Vows to Defeat Alzheimer’s

The Associated Press reports that French President Nicholas Sarkozy has declared his commitment to curing Alzhemier’s Disease as he visited a retirement home and geriatric hospital wing in Dax, France. Before winning this year’s election, he in May asserted the importance of “doctors with the means to find the solution. The objective must be the […]

Continue reading


Neuropsychology

Neuropsychology — which examines how human behavior, cognition, and emotion relate to the brain — is one of many fields that the Roskamp Institute uses to address health issues related to memory and Alzeheimer’s. For more information about it, read the journal titled Neuropsychology.

Continue reading


Sarasota’s Roskamp Institute Announces Participation in Multiple Sclerosis Study

We have just put out a press release announcing the Roskamp Institute’s participation in a multiple sclerosis study. Here’s a quote from Michael Mullan: “We are looking for volunteers to participate in this pharmaceutical sponsored research study to assess the effectiveness and safety of the investigational drug fingolimod, used to treat patients with relapsing-remitting MS,” […]

Continue reading


Roskamp Institute recruiting for clinical trials

One of the key aspects of our research at the Roskamp Institute is clinical trials.  Without qualified volunteers, our work is impossible. We are currently recruiting volunteers for our clinical trials, which are run by our Scientific Director, Michael Mullan, MBBS, Ph.D.  We are currently recruiting for clinical trials on the following diseases. Alzheimer’s Disease […]

Continue reading


Roskamp Institute Announces New Class Of Drugs That Can Impact Alzheimer’s Disease

On January 25th, we announceed the discovery of a new class of drugs that lower the production of the main pathological protein that causes Alzheimer’s diseas. Our annoucement got picked up in the press. Following is a roundup of press mentions: Sarasota’s Roskamp Institute Discovers New Class Of Drugs That Can Impact Alzheimer’s Disease Medical […]

Continue reading